Evaluation of Nasal Congestion Clinical Efficacy for Diphenhydramine 25 mg and Diphenhydramine 50 mg in Seasonal Allergic Rhinitis: a Randomized, Double-blind, Placebo and Pseudoephedrine Controlled Study

Brief Summary

Detailed Description

Subjects who met the inclusion/exclusion criteria were enrolled into the placebo run-in phase of the study on Day -7 (prerandomization, Visit 1). Baseline symptom scores were established during this run-in phase. Subjects with moderate nasal congestion who took at least 80% of their study medication during the run-in phase were eligible for enrollment in the two-week double-blind phase of the study and were randomized on Day 1 (randomization, Visit 2). They were treated for two weeks with their assigned medication. The severity of signs/symptoms were evaluated by the subjects every morning and night and by the investigator at each visit on Day 7 and Day 14. In addition, the subject and investigator provided a global evaluation of response to treatment on Day 7 and Day 14. Safety was evaluated by adverse events reported during the study, vital signs, and the incidence of somnolence.

Primary Outcomes

Secondary Outcomes

• Change from baseline in the subject's mean reflective Total Nasal Symptom (TNS) Score(14 Days)
• Change from baseline in the subject's mean instantaneous TNS Score(14 Days)
• Change from baseline in the subject's mean reflective Total SAR Symptom (TSS) Score(14 Days)
• Change from baseline in the subject's mean instantaneous TSS Score(14 Days)
• Change from baseline in the subject's mean reflective score for each of the seven remaining individual SAR symptoms, excluding nasal congestion/stuffiness(14 Days)
• Change from baseline in the subject's mean instantaneous score for each of the eight individual SAR symptoms(14 Days)
• Onset of action for diphenhydramine treatment for nasal congestion/stuffiness was determined by comparing the change from baseline in the subject's instantaneous nasal congestion/stuffiness scores for diphenhydramine versus placebo(taken at 15, 30, 60 and 90 minutes after the initial dose. Baseline was the score taken just prior to the initial dose.)
• Onset of action for diphenhydramine treatment for allergic rhinitis symptoms was determined by comparing the change from baseline in the subject's instantaneous TNS scores for diphenhydramine versus placebo(taken at 15, 30, 60 and 90 minutes after the initial dose. Baseline was the score taken just prior to the initial dose)
• Duration of action for diphenhydramine for treatment of nasal congestion/stuffiness was evaluated by comparing the change from baseline in the subject's mean instantaneous nasal congestion/stuffiness scores for diphenhydramine versus placebo(taken at the six-hour trough (just prior to the 8:00 pm dose) and the 12-hour trough (just prior to the 8:00 am dose))
• Duration of action for diphenhydramine for treatment of allergic rhinitis symptoms was evaluated by comparing the change from baseline in the subject's mean instantaneous TNS scores for diphenhydramine versus placebo(taken at the six-hour trough (just prior to the 8:00 pm dose) and the 12-hour trough (just prior to the 8:00 am dose))
• Time to maximal effect was assessed by a by-day analysis of the primary efficacy endpoint and select secondary endpoints(14 Days)
• Subject's global evaluation of response to treatment(at Visits 3 and 4, analyzed separately at each visit)
• Change from baseline in the Investigator's TNS score(at Visits 3 and 4, analyzed separately for each visit. Baseline was the score at Visit 1)
• Change from baseline in the Investigator's TSS score(at Visits 3 and 4, analyzed separately for each visit. Baseline was the score at Visit 1)
• Change from baseline for each of the eight individual Investigator's SAR symptoms(at Visits 3 and 4, analyzed separately for each visit. Baseline was the score at Visit 1)
• Investigator's global evaluation of the subject's response to treatment(at Visits 3 and 4, analyzed separately for each visit)
• Number and percentage of subjects experiencing adverse events(Duration of study)
• Change from baseline and potentially clinically important vital signs (systolic and diastolic blood pressure, pulse, and respiratory rate)(Duration of study)
• Occurrence of somnolence(Overall and weekly)